ResearcherOslo University HospitalActive in the last 2 years
Lars Aabakken
Matched on ORCID iD 0000-0002-3622-3826; OpenAlex author ID A5013603537. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2023: 1 paper · 2024: 3 papers
Papers 4
- Performance and safety of diagnostic EUS FNA/FNB and therapeutic ERCP in patients with borderline resectable and locally advanced pancreatic cancer - results f… Co-author DOI 10.1080/00365521.2023.2290456↗
- Molecular testing for personalized therapy is underutilized in patients with borderline resectable and locally advanced pancreatic cancer - real world data fro… Co-author DOI 10.1080/00365521.2024.2373115↗
- Clinicopathologic characteristics and treatment outcomes of pancreatic cancer patients at a tertiary referral hospital in Kenya. Last author DOI 10.3332/ecancer.2024.1682↗
- Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective coho… Co-author DOI 10.1093/bjsopen/zrad137↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ingvild Farnes · 3 shared papers, 2023–2024 · strength 0.71
- Paper Molecular testing for personalized therapy is underutilized in patients with borderline resectable and locally advanced… DOI 10.1080/00365521.2024.2373115↗
- Paper Performance and safety of diagnostic EUS FNA/FNB and therapeutic ERCP in patients with borderline resectable and locall… DOI 10.1080/00365521.2023.2290456↗
- Paper Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data f… DOI 10.1093/bjsopen/zrad137↗
- Caroline Sophie Verbeke · 3 shared papers, 2023–2024 · strength 0.71
- Paper Molecular testing for personalized therapy is underutilized in patients with borderline resectable and locally advanced… DOI 10.1080/00365521.2024.2373115↗
- Paper Performance and safety of diagnostic EUS FNA/FNB and therapeutic ERCP in patients with borderline resectable and locall… DOI 10.1080/00365521.2023.2290456↗
- Paper Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data f… DOI 10.1093/bjsopen/zrad137↗
- Knut Jørgen Labori · 3 shared papers, 2023–2024 · strength 0.71
- Paper Molecular testing for personalized therapy is underutilized in patients with borderline resectable and locally advanced… DOI 10.1080/00365521.2024.2373115↗
- Paper Performance and safety of diagnostic EUS FNA/FNB and therapeutic ERCP in patients with borderline resectable and locall… DOI 10.1080/00365521.2023.2290456↗
- Paper Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data f… DOI 10.1093/bjsopen/zrad137↗
- Sheila W. Muchiri · 1 shared paper, 2024 · strength 0.31
- Svein Dueland · 1 shared paper, 2023 · strength 0.18
- Dyre Berg Kleive · 1 shared paper, 2023 · strength 0.18
- Pål‐Dag Line · 1 shared paper, 2023 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.